Overview

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Status:
Completed
Trial end date:
2019-10-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ProQR Therapeutics